Fosamax and Osteonecrosis of the Jaw: Causation and Risk – What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure: A Legacy of Informed Decision-Making

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and their management. Within this broad context, discussions on bone health and therapeutic interventions have been central, particularly regarding the use of medications to address osteoporosis and related disorders. This heritage emphasizes the importance of informed decision-making and awareness of potential side effects associated with pharmaceutical treatments. As the focus narrows from general health education to specific occupational exposure concerns, a critical pivot emerges. In mass production environments, workers may encounter materials or processes that involve exposure to substances with known health implications. The transition from a general health perspective to an occupational setting requires careful consideration of how workplace conditions can influence health outcomes. This shift underscores the need to examine the relationship between occupational exposure and specific health risks, moving beyond broad health information to targeted inquiries. The concern now centers on how such exposures in manufacturing contexts might relate to adverse effects previously discussed in clinical or general health literature, without delving into mechanistic details. This pivot sets the stage for a focused examination of exposure scenarios in mass production settings.

Bridging General Health Knowledge to Specific Risk: Fosamax and Osteonecrosis of the Jaw

Building on the foundation of general health education, this section transitions to a specific medical risk: the association between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves pain, swelling, and exposed bone in the oral cavity, often following dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection.

Mechanistic Insights and Risk Factors for Fosamax-Associated ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover, which may impair the jawbone's ability to repair microdamage and respond to local stressors. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the jawbone's unique structure and remodeling dynamics may make it particularly vulnerable to the effects of bisphosphonates. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Evidence of Causation: Temporal Relationship and Dose-Response Data

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides evidence of a dose-response relationship, with longer exposure associated with higher risk, supporting a causal link.

Adequacy of Warnings and Clinical Recommendations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 about osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. Similarly, the label for Fosamax Plus D includes a comparable warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide information to healthcare providers and patients about the potential risk. In summary, the evidence indicates that Fosamax use is associated with an increased risk of osteonecrosis of the jaw, particularly with longer duration of use and in the presence of other risk factors. The prescribing information includes warnings about this risk, and mechanistic studies suggest that bisphosphonate-induced suppression of bone turnover may contribute to the condition. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the rare but serious risk of ONJ, and consider dental evaluations before initiating therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with an increased risk of osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. The risk is higher with longer duration of use and in the presence of other risk factors such as invasive dental procedures, cancer, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What does the research say about the dose-response relationship between Fosamax and ONJ?

A cohort study using the UK Clinical Practice Research Datalink found that the risk of ONJ was threefold higher after 2-3 years of Fosamax treatment and eightfold higher after 10 years compared to past use, indicating a dose-response relationship. Absolute risks remained low, approximately 0.05% after 5 years (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Are there adequate warnings about ONJ in Fosamax prescribing information?

Yes, the prescribing information for Fosamax includes a specific warning (section 5.4) about osteonecrosis of the jaw, describing the risk and associated factors. The label for Fosamax Plus D also contains a comparable warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.